CLINICAL TRIALS PROFILE FOR PROTEIN C CONCENTRATE HUMAN
✉ Email this page to a colleague
All Clinical Trials for protein c concentrate human
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00046514 ↗ | ABI-007 in Taxol Resistant Patients With Metastatic Breast Cancer | Completed | Celgene Corporation | Phase 2 | 2001-06-01 | The anticancer agent paclitaxel (marketed as Taxol) has shown remarkable activity against metastatic breast cancer. However, the Taxol formulation requires prolonged administration times, and there are safety problems that have been attributed to the solvent rather than the active ingredient, paclitaxel. This is a new formulation of paclitaxel that has been found to have fewer safety problems than Taxol, and may be administered safely at higher doses. This study will investigate the safety and efficacy of this new formulation of paclitaxel given intravenously once a week for three weeks, followed by a rest week. This cycle will be repeated until safety problems or treatment failure require that the patient stop therapy. |
| NCT00157118 ↗ | Efficacy and Safety Study of Protein C Concentrate in Subjects With Severe Congenital Protein C Deficiency | Completed | Baxalta now part of Shire | Phase 2/Phase 3 | 2003-08-22 | The purpose of this study is to show that Protein C Concentrate is a safe and effective treatment for subjects with congenital protein C deficiency. Depending on the type of treatment required, patients are assigned to one of 3 study parts: Part 1 is for the treatment of acute episodes, Part 2 is for short-term prophylaxis, and Part 3 is for long-term prophylaxis in infants aged less than 6 months only. |
| NCT00157118 ↗ | Efficacy and Safety Study of Protein C Concentrate in Subjects With Severe Congenital Protein C Deficiency | Completed | Baxalta US Inc. | Phase 2/Phase 3 | 2003-08-22 | The purpose of this study is to show that Protein C Concentrate is a safe and effective treatment for subjects with congenital protein C deficiency. Depending on the type of treatment required, patients are assigned to one of 3 study parts: Part 1 is for the treatment of acute episodes, Part 2 is for short-term prophylaxis, and Part 3 is for long-term prophylaxis in infants aged less than 6 months only. |
| NCT00161720 ↗ | Retrospective Study to Capture Dosing and Treatment Outcome Data in Participants With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND | Completed | Baxalta now part of Shire | 2005-06-01 | This is a data collection study with the purpose of capturing dosing and treatment outcome data in participants with severe congenital protein C deficiency who were treated with protein C concentrate under an Emergency Use Investigational New Drug Application (IND). | |
| NCT00161720 ↗ | Retrospective Study to Capture Dosing and Treatment Outcome Data in Participants With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND | Completed | Baxalta US Inc. | 2005-06-01 | This is a data collection study with the purpose of capturing dosing and treatment outcome data in participants with severe congenital protein C deficiency who were treated with protein C concentrate under an Emergency Use Investigational New Drug Application (IND). | |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for protein c concentrate human
Condition Name
Clinical Trial Locations for protein c concentrate human
Trials by Country
Clinical Trial Progress for protein c concentrate human
Clinical Trial Phase
Clinical Trial Sponsors for protein c concentrate human
Sponsor Name
